Genexine's anemia drug matches Roche-CSL product in phase 3, laying groundwork for Asia filings

Genexine has laid down a marker in its bid to challenge for the chronic kidney disease (CKD)-induced anemia field, showing that its investigational drug candidate matched Roche and CSL Vifor’s Mircera in an interim look at phase 3 data.